As Cytokinetics’s ALS drug fails Phase III, focus turns to cardiomyopathy candidate

San Francisco-based biotechnology company Cytokinetics has announced that it will be winding down the Phase III trial of its amyotrophic lateral sclerosis pipeline drug, reldesemtiv, as they found no evidence of an effect compared to a placebo on primary or secondary endpoints.